Recommendations for measuring HIV reservoir size in cure-directed clinical trials

The BEAT-HIV Delaney Collaboratory to Cure HIV-1 infection

Research output: Contribution to journalArticlepeer-review

86 Scopus citations


Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will require a consensus on how best to measure the numbers of persistently infected cells with the potential to cause viral rebound after antiretroviral-therapy cessation in assessing the results of cure-directed strategies in vivo. Current measurements assess various aspects of the HIV provirus and its functionality and produce divergent results. Here, we provide recommendations from the BEAT-HIV Martin Delaney Collaboratory on which viral measurements should be prioritized in HIV-cure-directed clinical trials.

Original languageEnglish (US)
Pages (from-to)1339-1350
Number of pages12
JournalNature Medicine
Issue number9
StatePublished - Sep 1 2020

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'Recommendations for measuring HIV reservoir size in cure-directed clinical trials'. Together they form a unique fingerprint.

Cite this